We present the case of a patient with an elevated prostate-specific antigen level who underwent a prostate MRI that revealed a mass between the prostate and rectum, prompting further evaluation.

Is now the time to buy this exciting healthcare stock? The post Exciting clinical news for this ASX healthcare stock earns it a buy recommendation appeared first on The Motley Fool Australia.

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Early-stage prostate cancer rarely causes symptoms, making routine screening the most reliable way to catch it before it ...

aDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China bDepartment of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University ...

Low testosterone levels may increase the risk of higher-grade progression in prostate cancer patients under active ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced ...

A PSA test in midlife could help to identify men at low risk of prostate cancer, supporting screening strategies and reducing overdiagnosis.

In people with type 2 diabetes in the world's richest countries, deaths from cardiovascular disease are declining while mortality ​from dementia is on the rise, a large analysis has found.

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer.